The Drug Eluting Stents Center

Filter Your Results




One Question… How Will You Apply Drug-eluting Stents in Your SFA Practice?

August 2012—Featuring Gary M. Ansel, MD; Bruce H. Gray, DO, MSVM, FSCAI; John H. Rundback, MD; and Evan Lipsitz, MD

Zilver PTX Drug-Eluting Stent Trial Shows Superior 3-Year TLR Rates in Femoropopliteal Disease Treatment

August 13, 2012 -- Cook Medical (Bloomington, IN) announced new 3-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Di…

Cook Launches Zilver PTX in Australia to Treat SFA Disease

May 21, 2012 -- Cook Medical (Bloomington, IN) announced the Australian launch of the Zilver PTX paclitaxel-eluting peripheral stent for treating lesions in the superficial fe…

Cook’s Zilver PTX Stent Approved in Japan

March 1, 2012 -- Cook Medical (Bloomington, IN) announced that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency to sell the Zilver PTX pa…

FDA Panel Recommends Approval of Cook’s Zilver PTX Stent to Treat SFA Disease

October 13, 2011 -- Cook Medical (Bloomington, IN) announced that the company’s Zilver PTX drug-eluting stent for treating peripheral artery disease in the superficial f…

Below-the-Knee Drug-Eluting Stents

Andrew J. Feiring, MD, FACC, FSCAI

August 2011—Is there a role for this readily available device in treating critical limb ischemia?

Cook’s Zilver PTX Compares Favorably to PTA for SFA Treatment in Diabetic Patients

June 18, 2011 -- The Society for Vascular Surgery (SVS) announced that results of a prospective, randomized trial indicate that the Zilver PTX paclitaxel-eluting stent (Cook M…

Cordis to Exit Drug-Eluting Stent Market

June 15, 2011 -- Cordis Corporation (Bridgewater, NJ) announced it will no longer pursue the development of the Nevo sirolimus-eluting coronary stent and will also stop manufa…




Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.